Back to Browse Journals » Stem Cells and Cloning: Advances and Applications » Volume 3

Neural stem cell sex dimorphism in aromatase (CYP19) expression: a basis for differential neural fate

Authors Jay Waldron, Althea McCourty, Laurent Lecanu

Published Date November 2010 Volume 2010:3 Pages 175—182

DOI http://dx.doi.org/10.2147/SCCAA.S15200

Published 22 November 2010

Jay Waldron1, Althea McCourty1, Laurent Lecanu1,2
1The Research Institute of the McGill University Health Centre, Montreal, Canada; 2Department of Medicine, McGill University, Quebec, Canada

Purpose: Neural stem cell (NSC) transplantation and pharmacologic activation of endogenous neurogenesis are two approaches that trigger a great deal of interest as brain repair strategies. However, the success rate of clinical attempts using stem cells to restore neurologic functions altered either after traumatic brain injury or as a consequence of neurodegenerative disease remains rather disappointing. This suggests that factors affecting the fate of grafted NSCs are largely understudied and remain to be characterized. We recently reported that aging differentially affects the neurogenic properties of male and female NSCs. Although the sex steroids androgens and estrogens participate in the regulation of neurogenesis, to our knowledge, research on how gender-based differences affect the capacity of NSCs to differentiate and condition their neural fate is lacking. In the present study, we explored further the role of cell sex as a determining factor of the neural fate followed by differentiating NSCs and its relationship with a potential differential expression of aromatase (CYP19), the testosterone-metabolizing enzyme.
Results: Using NSCs isolated from the subventricular zone of three-month-old male and female Long-Evans rats and maintained as neurospheres, we showed that differentiation triggered by retinoic acid resulted in a neural phenotype that depends on cell sex. Differentiated male NSCs mainly expressed markers of neuronal fate, including ßIII-tubulin, microtubule associated protein 2, growth-associated protein 43, and doublecortin. In contrast, female NSCs essentially expressed the astrocyte marker glial fibrillary acidic protein. Quantification of the expression of aromatase showed a very low level of expression in undifferentiated female NSCs, whereas aromatase expression in male NSCs was 14-fold greater than the female level.
Conclusion: Our results confirm our previous data that the neural phenotype acquired by differentiating NSCs largely depends on cell sex, and that differential expression of aromatase in undifferentiated NSCs might contribute to this sex-based dimorphism. Although still preliminary, our discovery may have clinical application in the development of future brain repair strategies.

Keywords: neuroregenerative medicine, brain repair strategy, sex dimorphism, aromatase, adult stem cells

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Age and sex differences in neural stem cell transplantation: a descriptive study in rats

Waldron J, Lecanu L

Stem Cells and Cloning: Advances and Applications 2011, 4:25-37

Published Date: 11 April 2011

Aging differentially affects male and female neural stem cell neurogenic properties

Jay Waldron, Althea McCourty, Laurent Lecanu

Stem Cells and Cloning: Advances and Applications 2010, 3:119-127

Published Date: 1 September 2010

Readers of this article also read:

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets

Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, Lee M, Seo JW, Park ES

Drug Design, Development and Therapy 2015, 9:695-706

Published Date: 30 January 2015

Progressive osseous heteroplasia: diagnosis, treatment, and prognosis

Pignolo RJ, Ramaswamy G, Fong JT, Shore EM, Kaplan FS

The Application of Clinical Genetics 2015, 8:37-48

Published Date: 30 January 2015

Diabetes reversal via gene transfer: building on successes in animal models

Gerace D, Martiniello-Wilks R, Simpson AM

Research and Reports in Endocrine Disorders 2015, 5:15-29

Published Date: 29 January 2015

Corrigendum

Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Erratum

Schuelert N, Russell FA, McDougall JJ

Orthopedic Research and Reviews 2011, 3:9-10

Published Date: 1 March 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010